Jingting Jiang

ORCID: 0000-0002-3128-9762
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Cancer Immunotherapy and Biomarkers
  • Immune Cell Function and Interaction
  • Immunotherapy and Immune Responses
  • CAR-T cell therapy research
  • Cancer-related molecular mechanisms research
  • MicroRNA in disease regulation
  • Immune cells in cancer
  • RNA modifications and cancer
  • Circular RNAs in diseases
  • Cancer Cells and Metastasis
  • Gastric Cancer Management and Outcomes
  • Cancer-related gene regulation
  • Cancer Research and Treatments
  • Epigenetics and DNA Methylation
  • Peptidase Inhibition and Analysis
  • IL-33, ST2, and ILC Pathways
  • Galectins and Cancer Biology
  • Esophageal Cancer Research and Treatment
  • RNA Research and Splicing
  • Cancer Mechanisms and Therapy
  • Lung Cancer Treatments and Mutations
  • Cancer, Lipids, and Metabolism
  • Ovarian cancer diagnosis and treatment
  • Ferroptosis and cancer prognosis
  • T-cell and B-cell Immunology

Soochow University
2016-2025

Nanjing Medical University
2025

The First People's Hospital of Changzhou
2014-2024

Yangzhou University
2023-2024

Nanjing University
2022-2024

Soochow University
2012-2023

Memorial Sloan Kettering Cancer Center
2023

Jilin Province Tumor Hospital
2016-2017

Shanghai Institutes for Biological Sciences
2016

Shanghai Jiao Tong University
2016

Abstract Background It has been well established that circular RNAs (circRNAs) play an important regulatory role during tumor progression. Recent studies have indicated even though circRNAs generally regulate gene expression through miRNA sponges, they may encode small peptides in pathogenesis. However, it remains largely unexplored whether are involved the tumorigenesis of colon cancer (CC). Methods The profiles CC tissues were assessed by circRNA microarray. Quantitative real-time PCR,...

10.1186/s12943-019-1010-6 article EN cc-by Molecular Cancer 2019-03-29

Abstract Purpose: Radiofrequency ablation (RFA) has been shown to elicit tumor-specific T-cell immune responses, but is not sufficient prevent cancer progression. Here, we investigated immune-suppressive mechanisms limiting the efficacy of RFA. Experimental Design: We performed a retrospective case-controlled study on patients with synchronous colorectal liver metastases who had received primary tumor resection or without preoperative RFA for metastases. Tumor-infiltrating T cells and...

10.1158/1078-0432.ccr-15-1352 article EN Clinical Cancer Research 2016-02-29

Abstract Systemic immune-inflammation index (SII), based on peripheral lymphocyte, neutrophil, and platelet counts, was recently investigated as a prognostic marker in several tumors. However, SII has not been reported esophageal squamous cell carcinoma (ESCC). We evaluated the value of 916 patients with ESCC who underwent radical surgery. Univariate multivariate analyses were calculated by Cox proportional hazards regression model. The time-dependent receiver operating characteristics (ROC)...

10.1038/srep39482 article EN cc-by Scientific Reports 2016-12-21

Cancer immunotherapy has shown great promise as a new standard cancer therapeutic modality. However, the response rates are limited for current approach that depends on enhancing spontaneous antitumor immune responses. Therefore, increasing tumor immunogenicity by expressing appropriate cytokines should further improve immunotherapy. IL-33 is member of IL-1 family and released necrotic epithelial cells or activated innate thus considered "danger" signal. The role in promoting type 2...

10.4049/jimmunol.1401344 article EN The Journal of Immunology 2014-11-27

Pre-metastatic niche formation is critical for the colonization of disseminated cancer cells in distant organs. Here we find that lung mesenchymal stromal (LMSCs) at pre-metastatic stage possess potent metastasis-promoting activity. RNA-seq reveals an upregulation complement 3 (C3) those LMSCs. C3 found to promote neutrophil recruitment and extracellular traps (NETs), which facilitate cell metastasis lungs. expression LMSCs induced sustained by Th2 cytokines a STAT6-dependent manner....

10.1038/s41467-021-26460-z article EN cc-by Nature Communications 2021-10-27

Abstract Background N‐acetyltransferase 10 ( NAT10 ) is the only enzyme known to mediate N4‐acetylcytidine (ac4C) modification of mRNA and crucial for stability translation efficiency. However, its role in cancer development prognosis has not yet been explored. This study aimed examine possible colon cancer. Methods The expression levels were evaluated by immunohistochemical analyses with a tissue microarray, prognostic value patients was further analyzed. Quantitative real‐time polymerase...

10.1002/cac2.12363 article EN cc-by-nc-nd Cancer Communications 2022-10-08

The tumor microenvironment (TME) is the internal environment of malignant progression, and host antitumor immune response normal tissue destruction occur in TME. Tumor-infiltrating lymphocytes (TIL) a crucial component TME reflect response. purpose this study was to discuss methodology for TIL evaluation assess prognostic value gastric cancer. In total, we reviewed 1033 gastrectomy cases between 2002 2008 at Third Affiliated Hospital Soochow University. To understand cancer (GC), were...

10.3389/fimmu.2019.00071 article EN cc-by Frontiers in Immunology 2019-01-28

This study was aimed to detect the correlation among EGFR/KRAS status and PD-1/PD-L1 expression in non-small-cell lung cancer (NSCLC) patients. PD-1 PD-L1 expressions were detected by immunohistochemistry 100 surgically resected adenocarcinoma tissues statistically correlated with clinicopathological characteristics including EGFR KRAS statuses. Besides, overall survival (OS) times analyzed. There a statistical significances between tumor (P = 0.043), higher mutation rate lower significance...

10.1080/15384047.2016.1156256 article EN Cancer Biology & Therapy 2016-03-08

To determine the long-term efficacy of adjuvant immunotherapy with autologous cytokine-induced killer (CIK) cells for locally advanced gastric cancer patients.One hundred and fifty-one patients stage III/IV who had undergone gastrectomy were enrolled, assigned to two groups (immunotherapy group versus no group/or control group), followed.The 5-year overall survival (OS) disease-free (DFS) rates 32.4 23.4 % (P = 0.071) 28.3 10.4 0.044), respectively. For intestinal-type tumors, OS DFS...

10.1007/s00262-012-1289-2 article EN cc-by Cancer Immunology Immunotherapy 2012-06-06

Abstract Hepatocellular carcinoma (HCC) is one of the leading cause cancer death in world. Fructose-1,6-biphosphatase (FBP1), a rate-limiting enzyme gluconeogenesis, has been identified recently as tumor suppressor HCC and other types. In this study, we demonstrated that tripartite motif-containing protein 28 (TRIM28) binds directly to promotes FBP1 for ubiquitination degradation. MAGE-A3 MAGE-C2, which are known be overexpressed HCC, can enhance TRIM28-dependent degradation by forming...

10.1038/oncsis.2017.21 article EN cc-by Oncogenesis 2017-04-10

Background/Aims: PD-L1 (Programmed cell death 1 ligand 1, PD-L1), an essential immune checkpoint molecule in the tumor microenvironment, is important target for cancer immunotherapy. We have previously reported that its expression human gastric and esophageal tissues significantly associated with progression patients’ postoperative prognoses. Its cells well known to inhibit T cell-mediated anti-tumor response, this mechanism of action has been targeted As now, autonomous effect on not...

10.1159/000480000 article EN cc-by-nc-nd Cellular Physiology and Biochemistry 2017-01-01

Abstract Circular RNA (circRNA) plays an important role in the development of human malignant tumors. Recently, increasing number circRNAs have been identified and investigated various However, expression pattern biological function colorectal cancer (CRC) still remain largely unexplored. In present study, hsa_circ_0009361 was significantly down-regulated CRC tissues cells. Low level promoted proliferation, epithelial–mesenchymal transition (EMT), migration, invasion Hsa_circ_0009361 as...

10.1042/cs20190286 article EN Clinical Science 2019-05-01
Coming Soon ...